It is hard to get excited after looking at Becton Dickinson's (NYSE:BDX) recent performance, when its stock has declined 24% over the past three months. We, however decided to study the company's ...

We came across a bullish thesis on Becton, Dickinson and Company on Disruptive Analytics’ Substack by Magnus Ofstad. In this ...

Medtronic is bringing on a medical device industry veteran for its new top lawyer as it prepares for a major organizational ...

Fong replaced Brad Lerman as Medtronic’s GC, who retired in 2022 before being lured out of retirement to become CLO at ...

This was the stock's second consecutive day of gains.

According to the Adhishthana Principles, a stock begins forming its Cakra from Phase 4, with the formation typically ...

To enable awareness and knowledge-sharing around best practices of atherothrombectomy in the treatment of vascular diseases a ...

Learn about the executive team and board of directors at Becton Dickinson & Co (BDX:XNYS) and review their bios and compensation over the latest fiscal years.

The "Blood Market 2025-2029" has been added to ResearchAndMarkets.com's offering. The global blood market is poised to expand by USD 2.59 billion from 2024 to 2029, with an anticipated CAGR of 5.7%.

Becton Dickinson & Co Becton Dickinson & Co BDX Stock XNYS Rating as of Jul 4, 2025 Read Company Report Download PDF ...